INVESTORS & MEDIA

Regeneron Announces Presentation at the Leerink Swann Novel Cancer Therapeutics Roundtable ConferenceTARRYTOWN, N.Y.--(BUSINESS WIRE)--May. 15, 2009-- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference on Wednesday, May 20, 2009. The presentation, which is scheduled for 11:00 a.m. Eastern Time, will provide a brief overview of the Company and include a question-and-answer session with a Leerink Swann analyst. The session may be accessed through the Company’s web site, www.regeneron.com, on the Investor Relations page under the Presentations heading. An archived version of the presentation will be available after the live webcast through June 19, 2009. Additional information about Regeneron and recent news releases are available on the Regeneron web site.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST^® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.

Source: Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.
Investor Relations
Peter Dworkin, 914-345-7640
peter.dworkin@regeneron.com
or
Media Relations
Laura Lindsay, 914-345-7800
laura.lindsay@regeneron.com
or
Olga Fleming, 212-845-5636
ofleming@biosector2.com